Logotype for Myriad Genetics Inc

Myriad Genetics (MYGN) investor relations material

Myriad Genetics Piper Sandler 37th Annual Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Myriad Genetics Inc
Piper Sandler 37th Annual Healthcare Conference summary2 Dec, 2025

Product innovation and portfolio updates

  • MyRisk flagship product updated to include 63 genes, aligning with NCCN and ASCO guidelines.

  • Launched new products: FirstGene and Early Access for prenatal and hereditary cancer screening.

  • Prequel NIPS test now available at eight-week gestational age, earlier than competitors.

  • Prolaris test for prostate cancer to combine molecular and AI, launching first half of next year.

  • MRD assay, Precise MRD, to launch in first half of next year, with high sensitivity for low-shedding cancers.

Strategic focus and market positioning

  • Updated strategy prioritizes cancer care continuum for accelerated, profitable growth.

  • Mental health and prenatal health segments to grow at or above market rates.

  • Hereditary cancer remains foundational, with resurgence and significant market opportunity.

  • Bundling of tests (e.g., Prolaris and MyRisk) is increasing, leveraging EMR integration.

  • Partnerships, such as with PATHOMIQ, accelerate evidence generation and AI integration.

Financial performance and operational efficiency

  • Maintains industry-leading gross margins through efficient sample processing.

  • GeneSight test returned to mid-single-digit growth, with strong gross margin and expanded payer coverage.

  • Over 550,000 patients tested with GeneSight in 2023, generating $150M+ in revenue.

  • Margins expected to be impacted by MRD launch, with careful volume management planned.

  • Scale in MRD expected to reduce costs and support sustained, profitable growth.

MRD's impact on gross margins 2026-2027
Unaffected hereditary cancer growth drivers
Prolaris NCCN guideline strategy for 2026 growth
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Myriad Genetics earnings date

Logotype for Myriad Genetics Inc
Q4 202524 Feb, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Myriad Genetics earnings date

Logotype for Myriad Genetics Inc
Q4 202524 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Myriad Genetics, Inc. offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage